Analysis of clinical characteristics of 92 patients with paroxysmal nocturnal hemoglobinuria: A single institution experience in China. Issue 1 (10th September 2019)

• Record Type: Journal Article
• Authors: Fu, Rong; Li, Liyan; Li, Lijuan; Liu, Hui; Zhang, Tian; Ding, Shaoxue; Wang, Guojin; Song, Jia; Wang, Huaquan; Xing, Limin; Guan, Jing; Shao, Zonghong
• Is Part Of: Journal of clinical laboratory analysis. Volume 34:Issue 1(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-09-10
• Subjects: glucocorticoid -- paroxysmal nocturnal hemoglobinuria -- renal injury -- thrombosis; Diagnosis, Laboratory -- Periodicals; Medical laboratory technology -- Periodicals; 616
• DOI: 10.1002/jcla.23008
• Languages: English
• ISSNs: 0887-8013

Abstract

Abstract: Objectives: We performed a retrospective analysis to investigate the clinical characteristics and therapeutic strategies of Chinese paroxysmal nocturnal hemoglobinuria (PNH) patients, and assessed the efficacy and safety of glucocorticoid in PNH patients. Methods: The clinical data of 92 PNH cases in our hospital were analyzed, including clinical manifestation, laboratory examination, treatment efficacy, and survival. Results: The main clinical manifestations of these patients included hemoglobinuria, anemia, fatigue, dyspnea, headache, abdominal pain, and erectile dysfunction. Glucocorticoid is still the first‐line treatment for PNH patients to control hemolytic attack, and the short‐term remission rate (12 months) is 79.01% (64/81). Meanwhile, the overall survival (OS) of 10 years after diagnosis was estimated as 70.77% (46/65). Moreover, Cox proportional risk model for multivariate analysis showed that the increase in LDH multiple, thrombosis complications, and complicated with bone marrow failure were the independent adverse prognostic factors affecting the survival of PNH patients. Conclusion: Paroxysmal nocturnal hemoglobinuria patients in mainland China have various clinical features, while lower incidences of thrombosis and renal damage. Thrombosis and bone marrow failure are two complications with worse prognosis.